The efficacy of teneligliptin in diabetic patients on hemodialysis
Phase 4
- Conditions
- Type2 diabetic patients on hemodialysis
- Registration Number
- JPRN-UMIN000010999
- Lead Sponsor
- Kawashima Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Patients having infectious diseases, thyroid disease, or malignant tumors. Patients being treated with steroids.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary end-point is postprandial plasma glucose, glycated albumin or HbA1c measurement three months after new, additional administration of teneligliptin and change from alogliptin in type 2 diabetic patients on hemodialysis.
- Secondary Outcome Measures
Name Time Method Other laboratory data, hemodialytic indices and adverse events will be analyzed as well.